East Midlands Airport set for 'busiest weekend since Covid restrictions were lifted' It said it is putting in plans to cope with the extra demand Nottingham Post · Apr 7, 2022
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022 Biophytis SA (NASDAQ:BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is expected to start in 2H of 2022 in the SARA Phase 2 trial. In October 2021, sarconeos at the highest dose of 350 mg… Benzinga · Apr 7, 2022
No Evidence to Support Widespread Use of Fourth COVID Shot, Say EU Agencies EU health agencies said on Wednesday there was no evidence to support the use of a fourth dose of COVID-19 vaccines developed by Pfizer and Moderna in the general population, but they recommend a second booster for people aged 80 and above. There is no clear evidence in the European… Asharq Al-Awsat · Apr 6, 2022
3 Top-Rated Stocks for Value Investors to Consider The recent stock market correction has created a few attractive opportunities for investors because many stocks are now trading at reasonable valuations. Thus, it could be wise now to invest in fundamentally solid stocks Bristol-Myers (BMY), McKesson (MCK), and AGCO (AGCO). These names are currently trading at discounts compared to… StockNews.com · Apr 4, 2022
Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status Clovis Oncology Inc (NASDAQ:CLVS) announced positive topline data from the monotherapy arm of Phase 3 ATHENA-MONO trial of Rubraca (Rucaparib) as first-line maintenance treatment in ovarian cancer. Rubraca achieved the primary endpoint of significantly improved progression-free survival (PFS) compared with placebo (20.2 months vs. 9.2 months). The median PFS for the HRD-positive patient… Benzinga · Mar 31, 2022
Governments want COVID vaccine developers to aim higher in hunt for better shots As governments prepare to live with COVID-19, some are questioning how much to rely on drugmakers to adapt vaccines to ward off future virus variants amid signs of tension between companies and regulators over the best approach, according to several sources familiar with the matter. Reuters · Mar 31, 2022
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine The European Medicines Agency has started reviewing Sanofi SA (NASDAQ:SNY) and its partner GlaxoSmithKline Plc's (NYSE:GSK) application seeking conditional authorization for their COVID-19 vaccine. The vaccine candidate, Vidprevtyn, was already being evaluated under a rolling review by EMA. The drugmakers had earlier said that they would seek regulatory approval for their COVID-19 vaccine to be… Benzinga · Mar 30, 2022
EU regulator advises AstraZeneca's COVID drug be cleared The European Union's drug regulator says it's recommending that an antibody drug developed by AstraZeneca be authorized to help people avoid getting sick with the coronavirus The Independent UK · Mar 24, 2022
EMA Recommends Approval Of AstraZeneca's COVID-19 Therapy, Evusheld EMA's human medicines committee (CHMP) has Benzinga · Mar 24, 2022
Evelo Biosciences Shares Gain After Positive Data On Faster Release EDP1815 Capsule, Q4 Earnings In the Q4 earnings release, Evelo Biosciences Inc (NASDAQ:EVLO) shared results from an ongoing Phase 1 single-center trial in healthy volunteers that showed that a capsule with an improved release profile could deliver EDP1815 higher up in the small intestine. Benzinga · Mar 24, 2022
Moderna Says Infant Covid Vaccine Succeeded in Trial US biotech firm Moderna on Wednesday said it was pursuing regulatory approval for its Covid vaccine in children under six years old after the two-shot regimen was found to be safe and produced a strong immune response. Specifically, two doses of 25 micrograms given to babies, toddlers and preschoolers generated… Asharq Al-Awsat · Mar 24, 2022
AstraZeneca's COVID-19 Vaccine Expected To Win European Approval This Week: Reuters European Medicines Agency is expected to approve AstraZeneca Plc's (NASDAQ: AZN) antibody-based COVID-19 vaccine for preventing COVID-19 infections, Benzinga · Mar 23, 2022
Calliditas Expects EMA's CHMP Opinion For Nefecon In Q2 Calliditas Therapeutics AB (NASDAQ:CALT) says that the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) can be expected in Q2 of 2022. In its review of the marketing authorization application (MAA) for Nefecon, the CHMP has informed us that they will issue an… Benzinga · Mar 22, 2022
East Midlands Airport announces new flights with Flybe airline Daily flights to Amsterdam will start in April and the twice daily EMA-Belfast service commences in July Nottingham Post · Mar 22, 2022
Benzinga · Mar 21, 2022 NeuroSense Shares Surge Over 400% As FDA Clears Initiating Pharmacokinetic Study Of PrimeC NeuroSense Therapeutics Ltd (NASDAQ:NRSN) has received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects. PrimeC is a novel extended-release oral formulation composed of a fixed-dose combination of ciprofloxacin and celecoxib. PrimeC targets several key mechanisms of amyotrophic lateral sclerosis (ALS) that contribute to motor neuron degeneration,…
Benzinga · Mar 18, 2022 BTAI: Final Countdown to April 5, 2022 PDUFA Date for BXCL501… By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT
Benzinga · Mar 17, 2022 Dynavax Adjuvanted Clover Bio's COVID-19 Vaccine Booster Shows Durable Protection Against Omicron Clover Biopharmaceuticals Ltd's follow-up analysis for efficacy in the SPECTRA Phase 2/3 trial of SCB-2019 COVID-19 vaccine provided high and durable protection in individuals five months after the second dose. The follow-up analysis involved 26,400 individuals. Against any variant, efficacy was maintained at 100% against severe COVID-19 and 95% against COVID-19 associated…
France 24 · Mar 16, 2022 Did the European Medicines Agency say we should stop using Covid-19 boosters? After a clip from a press conference was published online, questions were raised on social media about the European Medicines Agency's opinion on Covid-19 booster vaccines. Elements of the presser were taken out of context and the EMA's full message got lost in some of the posts. FRANCE 24's Georgina…
Benzinga · Mar 11, 2022 Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce Orphazyme A/S's (NASDAQ:ORPH) board of directors has called for a court-mediated restructuring, prompting the second round of layoffs in less than a year. The in-court restructuring will determine whether any operations can continue if the Company can raise any capital or if it is prudent to sell all or some parts of…
Benzinga · Mar 11, 2022 European Recommendation On Valneva's COVID-19 Shot Pushed Into April Valneva SE (NASDAQ:VALN) now expects a positive recommendation from the European Medicines Agency (EMA) for its VLA2001 COVID-19 candidate vaccine in April. Earlier, the Company expected the European recommendation by the end of March. As announced in February, Valneva received a list of questions as part of the CHMP's initial assessment, to which…
Benzinga · Mar 9, 2022 Amryt Pharma's Q4 FY21 Sales, FY22 Guidance Shy Of Street Consensus Amryt Pharma Plc's (NASDAQ:AMYT) Q4 FY21 sales increased 29% Y/Y to $54.8 million, missing the consensus of $56.81 million. The growth was driven by metreleptin revenues that increased 44% to $31.9 million. Cash of $113 million at December 31, 2021 (2020: $118.8M) The Company reported a wider operating loss of $(50.5) million…
The Guardian - UK · Feb 24, 2022 Covid: Iceland to lift all remaining curbs; coronavirus isolation rules end in England – as it happened Latest updates: Iceland confirms no extra restrictions for unvaccinated; people in England who test positive for Covid no longer have to self-isolate
Birmingham Post · Feb 23, 2022 Training provider moves into ex-Derby Telegraph offices EMA Training has created three floors of collaborative workspace, break-out areas, exam suites and meeting rooms
StockNews.com · Feb 22, 2022 5 Best Healthcare Stocks to Buy as a Hedge Against Inflation The healthcare sector has historically provided a better hedge against inflation than gold because of the inelastic demand for its products and services. Rising healthcare needs of an aging population, integration of advanced technologies, and breakthroughs in clinical trials brighten the sector’s prospects. Therefore, fundamentally-sound and undervalued healthcare stocks Sanofi…
Nottingham Post · Feb 22, 2022 East Midlands Airport TUI, Jet2, Ryanair: What airlines fly from there? Travel restrictions have eased and flight demand is rising from EMA